A federal watchdog said Tuesday it has begun auditing nursing homes’ use of the Patient Driven Payment Model to drive skilled ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a ...

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business HighlightsTMCnet News Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights [November ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

The MarketWatch News Department was not involved in the creation of this content. Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved ...

BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...